Latigo Biotherapeutics, Inc. Common Stock (LTGO) — Working Capital to Net Assets Ratio
Latigo Biotherapeutics, Inc. Common Stock (LTGO) has a Working Capital to Net Assets ratio of -12.8% as of March 2026. Working capital of $32.35 Million (current assets of $46.84 Million minus current liabilities of $14.49 Million) is measured against net assets of $-252.58 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. For the complete balance sheet picture, see Latigo Biotherapeutics, Inc. Common Stoc (LTGO) total assets.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Latigo Biotherapeutics, Inc. Common Stock Working Capital to Net Assets (2024–2025)
This chart shows how Latigo Biotherapeutics, Inc. Common Stock's Working Capital to Net Assets ratio has evolved across 2 annual periods from 2024 to 2025. As of March 2026, the ratio stands at -12.8%, reflecting working capital of $32.35 Million against net assets of $-252.58 Million USD. Explore LTGO debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Annual Working Capital to Net Assets for Latigo Biotherapeutics, Inc. Common Stock (2024–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Latigo Biotherapeutics, Inc. Common Stock from 2024 to 2025, covering 2 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Read LTGO liabilities breakdown for a breakdown of total debt and financial obligations.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -23.9% | $55.38 Million | $-231.67 Million | $73.83 Million | $18.45 Million | ▼ -18.7 pp |
| 2024 | -5.2% | $6.73 Million | $-129.60 Million | $21.16 Million | $14.44 Million | — |